[Quality and Structure of Outpatient Care for Adults with ADHD (Attention Deficit Hyperactivity Disorder) - Results of the RAABE-Study [Retrospective Data Analysis of ADHD Treatment in Adults]].
| Autor: | Thome J; Klinik und Poliklinik für Psychiatrie und Psychotherapie, Universitätsmedizin Rostock., Behnke K; Kassenärztliche Vereinigung Bayerns., Gleitz M; Medice Arzneimittel Pütter GmbH & Co. KG, Iserlohn., Steer L; Kassenärztliche Vereinigung Bayerns., Weiher M; Kassenärztliche Vereinigung Bayerns., Hasford J; Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie, Ludwig-Maximilians-Universität München. |
|---|---|
| Jazyk: | němčina |
| Zdroj: | Psychiatrische Praxis [Psychiatr Prax] 2019 Sep; Vol. 46 (6), pp. 317-323. Date of Electronic Publication: 2019 Aug 13. |
| DOI: | 10.1055/a-0880-1804 |
| Abstrakt: | Objective: Data on the quality and structure of outpatient care for adults with ADHD in Germany are scarce. The study describes the reality of care and identifies possible measures for improvement. Method: A complete survey of adults ≥ 18 years of age with a diagnosis of ADHD (ICD-Code F90.0) covered by statutory health insurance was carried out in the outpatient setting in the German Free State of Bavaria in 2012. Results: The analysis revealed a diagnostic prevalence of ADHD in adults in Bavaria of 0.1 %, which was lower than expected based on ADHD prevalence estimates in the general population (about 3 %). Patients were diagnosed by specialists for CNS disorders and by general practitioners. About 30 % of patients received a medication approved for the treatment of ADHD, and these were in approx. 75 % of cases prescribed by specialists for CNS disorders. About 50 % of the patients received psychotherapy. Conclusion: General practitioners play an important role for medical care of adult patients with ADHD. Continuous medical education programmes and collaboration between general practitioners and specialists is an urgent imperative for improving outpatient care of ADHD in adults. Competing Interests: Johannes Thome und Joerg Hasford haben von der KVB finanzielle Unterstützung für die eingereichte Arbeit erhalten. Johannes Thome hat darüber hinaus finanzielle Unterstützung (z. B. Vortragshonorare, Stipendien für Forschungsprojekte und wissenschaftliche Veranstaltungen, Mitgliedschaft in Beratungsgremien) erhalten von Actelion, AstraZeneca, Bristol-Meyers Squibb, Ever Neuro Pharma, Janssen-Cilag, Lilly, Lundbeck, Medice, Merz, Novartis, Pfizer, Roche, Servier, Shire, von denen einige Medikamente zur Behandlung der ADHS im Erwachsenenalter herstellen. Kerstin Behnke, Lydia Steer und Martina Weiher sind Mitarbeiterinnen der KV Bayerns. Markus Gleitz arbeitet hauptberuflich bei Medice. Die Kosten für die Open-Access-Veröffentlichung wurden von Medice getragen. (Owner and Copyright © Georg Thieme Verlag KG 2019.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|